Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cha University Industry-Academic Cooperation Foundation is managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, showing a high degree of individual attention per case. The portfolio spans 3 distinct art units, which indicates a broader technical reach than portfolios confined to a single unit. This diversification across 3 distinct art units suggests that the foundation's research covers multiple specialized sub-fields within the biotechnology sector.
The workload is distributed evenly among the examiners, with the busiest examiner, LOCKARD, JON MCCLELLAND, handling 1 pending office action. This means that each of the 4 distinct examiners is responsible for exactly 1 of the 4 pending office actions. The involvement of 3 distinct art units suggests that the foundation's research and development efforts are being evaluated across multiple specialized examination groups. This decentralized structure provides the foundation with a variety of examiner perspectives, reducing the risk associated with a single point of failure in the prosecution process and allowing for a more robust intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOCKARD, JON MCCLELLAND | 1 | 74.6% | +27.2% |
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| KIPOUROS, HOLLY MICHAELA | 1 | 69.5% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906165 | METHOD FOR PRODUCING BANKABLE AND SUBCULTURABLE MATURE MICROGLIA | SCHUBERG, LAURA J | 44d overdue |
| 18686643 | COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING POOR OVARIAN RESPONSE SYNDROME COMPRISING RGMC | LOCKARD, JON MCCLELLAND | — |
| 18291073 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ASHERMAN'S SYNDROME COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT | BOECKELMAN, JACOB A | — |
| 17782541 | BIOMIMETIC NERVE CHIP FOR EVALUATING EFFICACY AND TOXICITY ON NERVE, AND USE THEREOF | KIPOUROS, HOLLY MICHAELA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906165 | METHOD FOR PRODUCING BANKABLE AND SUBCULTURABLE MATURE MICROGLIA | SCHUBERG, LAURA J | 44d overdue |
| 18686643 | COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING POOR OVARIAN RESPONSE SYNDROME COMPRISING RGMC | LOCKARD, JON MCCLELLAND | — |
| 18291073 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ASHERMAN'S SYNDROME COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT | BOECKELMAN, JACOB A | — |
| 17782541 | BIOMIMETIC NERVE CHIP FOR EVALUATING EFFICACY AND TOXICITY ON NERVE, AND USE THEREOF | KIPOUROS, HOLLY MICHAELA | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1631 | 1 |
| 1799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686643 | COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING POOR OVARIAN RESPONSE SYNDROME COMPRISING RGMC | LOCKARD, JON MCCLELLAND | — | §101§102§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18291073 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ASHERMAN'S SYNDROME COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT | BOECKELMAN, JACOB A | 1655 | §102§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 17906165 | METHOD FOR PRODUCING BANKABLE AND SUBCULTURABLE MATURE MICROGLIA | SCHUBERG, LAURA J | 1631 | §103 | Non-Final OA | 44d overdue | Pending | Sep 12, 2022 |
| 17782541 | BIOMIMETIC NERVE CHIP FOR EVALUATING EFFICACY AND TOXICITY ON NERVE, AND USE THEREOF | KIPOUROS, HOLLY MICHAELA | 1799 | §103§112 | Final Rejection | — | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial